Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 250
- Registration Number
- NCT06572228
- Locations
- 🇺🇸
Henderson Clinical Trials, Henderson, Nevada, United States
🇺🇸Allergy, Asthma and Clinical Research Center, Oklahoma City, Oklahoma, United States
🇺🇸Clinical Research Associates of Central PA, DuBois, Pennsylvania, United States
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT06548100
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- Conditions
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 750
- Registration Number
- NCT06541704
- Locations
- 🇺🇸
Colorado Retina - Lakewood, Lakewood, Colorado, United States
🇺🇸Georgia Retina - Marietta, Marietta, Georgia, United States
🇺🇸Palmetto Retina Center, West Columbia, South Carolina, United States
Compassionate Use of Evinacumab
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT06500598
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 400
- Registration Number
- NCT06491914
- Locations
- 🇺🇸
Retina Group of New England, Waterford, Connecticut, United States
🇺🇸Florida Retina Institute, Orlando, Florida, United States
🇺🇸Retina Consultants of Southern Colorado, Colorado Springs, Colorado, United States
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
- Conditions
- Interventions
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT06469281
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey, United States
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT06465329
- Locations
- 🇺🇸
Orchard Healthcare Research Inc., Skokie, Illinois, United States
🇺🇸Detroit Clinical Research Center, Farmington Hills, Michigan, United States
🇺🇸University of Tennessee Medical Center, Knoxville, Tennessee, United States
A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 179
- Registration Number
- NCT06454630
- Locations
- 🇧🇬
Multi-profile Hospital for Active Treatment Hearth and Brain EAD, Pleven, Bulgaria
🇧🇬Multiprofile Hospital For Active Treatment Park Hospital Ltd., Plovdiv, Bulgaria
🇭🇺Budai Irgalmasrendi Korhaz, Budapest, Hungary
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT06452771
- Locations
- 🇳🇿
New Zealand Clinical Research, Christchurch, Canterbury, New Zealand
Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 224
- Registration Number
- NCT06444178
- Locations
- 🇬🇧
Fortrea Clinical Development, Leeds, United Kingdom